Profile

Dr. Beauchamp has an active research laboratory. He spent two years (1987-1989) conducting basic growth factor research in the Department of Cell Biology at Vanderbilt under the direction of Dr. Harold Moses after completion of his residency at UTMB. After two years in Dr. Moses' laboratory Dr. Beauchamp returned to UTMB as assistant professor in the departments of Surgery and Human Biological Chemistry and Genetics. His research fellowship was funded by the National Cancer Institute in the form of a Physician Scientist Award which supported his work for 5 years post-residency. Since completion of his surgical residency, Dr. Beauchamp's research work has maintained and has been continually funded by the NIH and other extramural funding agencies. He currently has three active R01 grants from the NIH, and is a project leader for the Gastrointestinal Cancer Specialized Program of Research Excellence (SPORE) Grant. Dr. Beauchamp's primary area of research interest has been in colorectal carcinogenesis, the biology of cancer cell invasion and metastasis, and in the identification of novel molecular biomarkers and therapeutic targets in colorectal and other alimentary tract malignancies.  His work applies DNA microarray and proteomic technology to identify novel biomarkers and therapeutic targets in human colorectal cancer samples.  He also uses molecular genetics and cell biological approaches to examine mechanistic questions in cancer biology in both cell culture and mouse models. In addition to the basic cancer research Dr. Beauchamp works in collaboration with his Medical Oncology and Radiation Oncology colleagues to accrue cancer patients to approved clinical trials.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Ma Y, Wang L, Neitzel LR, Loganathan S, Tang N, Qin L, Emily CE, Guo Y, Knapp S, Beauchamp RD, Lee E, Wang J (2016) Clin Cancer Res
    › Primary publication · 27678457 (PubMed)
  2. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X (2016) Sci Rep : 33273
    › Primary publication · 27623752 (PubMed) · PMC5021945 (PubMed Central)
  3. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. Gonzalez RS, Huh WJ, Cates JM, Washington K, Beauchamp RD, Coffey RJ, Shi C (2017) Histopathology 70(2): 223-231
    › Primary publication · 27560620 (PubMed)
  4. Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues. Chen X, Deane NG, Lewis KB, Li J, Zhu J, Washington MK, Beauchamp RD (2016) PLoS One 11(5): e0153784
    › Primary publication · 27176004 (PubMed) · PMC4866771 (PubMed Central)
  5. Optimization of a small molecule probe that restores e-cadherin expression. Brogan JT, Stoops SL, Brady S, An H, Weaver C, Daniels JS, Beauchamp RD, Lindsley CW, Waterson AG (2015) Bioorg Med Chem Lett 25(19): 4260-4
    › Primary publication · 26299347 (PubMed) · PMC4567403 (PubMed Central)
  6. Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. French CL, Ye F, Revetta F, Zhang B, Coffey RJ, Washington MK, Deane NG, Beauchamp RD, Weaver AM (2015) F1000Res : 99
    › Primary publication · 26097693 (PubMed) · PMC4457132 (PubMed Central)
  7. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. An H, Stoops SL, Deane NG, Zhu J, Zi J, Weaver C, Waterson AG, Zijlstra A, Lindsley CW, Beauchamp RD (2015) Oncotarget 6(26): 22934-48
    › Primary publication · 26082441 (PubMed) · PMC4673210 (PubMed Central)
  8. Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. Gonzalez RS, Cates JM, Washington MK, Beauchamp RD, Coffey RJ, Shi C (2016) Histopathology 68(2): 183-90
    › Primary publication · 25913616 (PubMed) · PMC4619179 (PubMed Central)
  9. Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Bhat AA, Pope JL, Smith JJ, Ahmad R, Chen X, Washington MK, Beauchamp RD, Singh AB, Dhawan P (2015) Oncogene 34(35): 4570-80
    › Primary publication · 25500541 (PubMed) · PMC4804637 (PubMed Central)
  10. Minority Underrepresentation in Academia: Factors Impacting Careers of Surgery Residents. Julien JS, Lang R, Brown TN, Aldrich MC, Deppen SA, Wu H, Feurer ID, Tarpley M, Hill G, Tarpley J, Beauchamp RD, Grogan EL (2014) J Racial Ethn Health Disparities 1(4): 238-246
    › Primary publication · 25396113 (PubMed) · PMC4226069 (PubMed Central)
  11. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Tripathi MK, Deane NG, Zhu J, An H, Mima S, Wang X, Padmanabhan S, Shi Z, Prodduturi N, Ciombor KK, Chen X, Washington MK, Zhang B, Beauchamp RD (2014) Cancer Res 74(23): 6947-57
    › Primary publication · 25320007 (PubMed) · PMC4252979 (PubMed Central)
  12. Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. Shi C, Washington MK, Chaturvedi R, Drosos Y, Revetta FL, Weaver CJ, Buzhardt E, Yull FE, Blackwell TS, Sosa-Pineda B, Whitehead RH, Beauchamp RD, Wilson KT, Means AL (2014) Lab Invest 94(4): 409-21
    › Primary publication · 24535260 (PubMed) · PMC3992484 (PubMed Central)
  13. Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. Zhu J, Wang J, Shi Z, Franklin JL, Deane NG, Coffey RJ, Beauchamp RD, Zhang B (2013) PLoS One 8(11): e79282
    › Primary publication · 24260186 (PubMed) · PMC3829853 (PubMed Central)
  14. Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. Al-Greene NT, Means AL, Lu P, Jiang A, Schmidt CR, Chakravarthy AB, Merchant NB, Washington MK, Zhang B, Shyr Y, Deane NG, Beauchamp RD (2013) PLoS One 8(7): e69660
    › Primary publication · 23922772 (PubMed) · PMC3726759 (PubMed Central)
  15. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Pope JL, Bhat AA, Sharma A, Ahmad R, Krishnan M, Washington MK, Beauchamp RD, Singh AB, Dhawan P (2014) Gut 63(4): 622-34
    › Primary publication · 23766441 (PubMed) · PMC4083824 (PubMed Central)
  16. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A (2013) Cancer Res 73(10): 2955-64
    › Primary publication · 23539446 (PubMed) · PMC3660148 (PubMed Central)
  17. Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS (2012) PLoS One 7(12): e51205
    › Primary publication · 23251453 (PubMed) · PMC3521008 (PubMed Central)
  18. A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. Shi M, Beauchamp RD, Zhang B (2012) PLoS One 7(7): e41292
    › Primary publication · 22844451 (PubMed) · PMC3402487 (PubMed Central)
  19. XIAP monoubiquitylates Groucho/TLE to promote canonical Wnt signaling. Hanson AJ, Wallace HA, Freeman TJ, Beauchamp RD, Lee LA, Lee E (2012) Mol Cell 45(5): 619-28
    › Primary publication · 22304967 (PubMed) · PMC3299836 (PubMed Central)
  20. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ╬▓-catenin. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD (2012) Gastroenterology 142(3): 562-571.e2
    › Primary publication · 22115830 (PubMed) · PMC3343368 (PubMed Central)
  21. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS (2012) Gut 61(9): 1291-8
    › Primary publication · 21997556 (PubMed) · PMC3419333 (PubMed Central)
  22. BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, Yeatman TJ, El-Rifai W, Beauchamp RD, Chang MS (2011) J Clin Invest 121(10): 4056-69
    › Primary publication · 21911938 (PubMed) · PMC3195453 (PubMed Central)
  23. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD, Dhawan P (2011) Gastroenterology 141(6): 2140-53
    › Primary publication · 21878201 (PubMed) · PMC3395068 (PubMed Central)
  24. The use of a multidisciplinary morbidity and mortality conference to incorporate ACGME general competencies. Kauffmann RM, Landman MP, Shelton J, Dmochowski RR, Bledsoe SH, Hickson GB, Beauchamp RD, Dattilo JB (2011) J Surg Educ 68(4): 303-8
    › Primary publication · 21708368 (PubMed) · PMC3128423 (PubMed Central)
  25. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB (2011) Oncogene 30(29): 3234-47
    › Primary publication · 21383692 (PubMed) · PMC3591522 (PubMed Central)
  26. Transformation of rat intestinal epithelial cells by overexpression of Rab25 is microtubule dependent. Lapierre LA, Caldwell CM, Higginbotham JN, Avant KM, Hall J, Beauchamp RD, Goldenring JR (2011) Cytoskeleton (Hoboken) 68(2): 97-111
    › Primary publication · 21246754 (PubMed) · PMC3885764 (PubMed Central)
  27. Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. Stoops SL, Pearson AS, Weaver C, Waterson AG, Days E, Farmer C, Brady S, Weaver CD, Beauchamp RD, Lindsley CW (2011) ACS Chem Biol 6(5): 452-65
    › Primary publication · 21241068 (PubMed) · PMC3401128 (PubMed Central)
  28. Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, Datta PK, Freeman ML (2010) Oncogene 29(25): 3703-14
    › Primary publication · 20440267 (PubMed) · PMC2892014 (PubMed Central)
  29. Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, Chen X, Aronow BJ, Yeatman TJ, Bhartur SG, Calhoun BC, Condie B, Manley NR, Beauchamp RD, Coffey RJ, Goldenring JR (2010) J Clin Invest 120(3): 840-9
    › Primary publication · 20197623 (PubMed) · PMC2827957 (PubMed Central)
  30. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD (2010) Gastroenterology 138(3): 958-68
    › Primary publication · 19914252 (PubMed) · PMC3388775 (PubMed Central)
  31. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P (2010) Oncogene 29(2): 305-12
    › Primary publication · 19881542 (PubMed) · PMC3388773 (PubMed Central)
  32. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Xu BJ, Li J, Beauchamp RD, Shyr Y, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM (2009) Mol Cell Proteomics 8(5): 936-45
    › Primary publication · 19164278 (PubMed) · PMC2689774 (PubMed Central)
  33. Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Smith JJ, Deane NG, Dhawan P, Beauchamp RD (2008) Surgery 144(3): 353-66
    › Primary publication · 18707034 (PubMed) · PMC2594010 (PubMed Central)
  34. Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. Kanies CL, Smith JJ, Kis C, Schmidt C, Levy S, Khabar KS, Morrow J, Deane N, Dixon DA, Beauchamp RD (2008) Mol Cancer Res 6(7): 1124-36
    › Primary publication · 18644977 (PubMed) · PMC2572152 (PubMed Central)
  35. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Li JQ, Xu BJ, Shakhtour B, Deane N, Merchant N, Heslin MJ, Washington K, Coffey RJ, Beauchamp RD, Shyr Y, Billheimer D (2007) Int J Oncol 31(1): 103-11
    › Primary publication · 17549410 (PubMed)
  36. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Shiou SR, Singh AB, Moorthy K, Datta PK, Washington MK, Beauchamp RD, Dhawan P (2007) Cancer Res 67(4): 1571-9
    › Primary publication · 17308096 (PubMed)
  37. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B (2007) Int J Radiat Oncol Biol Phys 67(2): 397-404
    › Primary publication · 17097833 (PubMed)
  38. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Johnson JC, Schmidt CR, Shrubsole MJ, Billheimer DD, Joshi PR, Morrow JD, Heslin MJ, Washington MK, Ness RM, Zheng W, Schwartz DA, Coffey RJ, Beauchamp RD, Merchant NB (2006) Clin Gastroenterol Hepatol 4(11): 1358-65
    › Primary publication · 16996805 (PubMed)
  39. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, Beauchamp RD (2006) J Biol Chem 281(45): 33971-81
    › Primary publication · 16959768 (PubMed)
  40. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Halder SK, Anumanthan G, Maddula R, Mann J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD, Datta PK (2006) Cancer Res 66(12): 6156-66
    › Primary publication · 16778189 (PubMed)
  41. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA (2006) Clin Cancer Res 12(5): 1570-6
    › Primary publication · 16533783 (PubMed)
  42. Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Grau AM, Datta PK, Zi J, Halder SK, Beauchamp RD (2006) Cell Signal 18(7): 1041-50
    › Primary publication · 16288847 (PubMed)
  43. E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Schmidt CR, Gi YJ, Patel TA, Coffey RJ, Beauchamp RD, Pearson AS (2005) Surgery 138(2): 306-12
    › Primary publication · 16153441 (PubMed)
  44. Cell proliferation: a matter of time and place. Deane NG, Parker MA, Beauchamp RD (2005) Surgery 138(1): 1-7
    › Primary publication · 16003308 (PubMed)
  45. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Halder SK, Beauchamp RD, Datta PK (2005) Neoplasia 7(5): 509-21
    › Primary publication · 15967103 (PubMed) · PMC1501161 (PubMed Central)
  46. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD (2005) J Clin Invest 115(7): 1765-76
    › Primary publication · 15965503 (PubMed) · PMC1150288 (PubMed Central)
  47. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Halder SK, Beauchamp RD, Datta PK (2005) Exp Cell Res 307(1): 231-46
    › Primary publication · 15922743 (PubMed)
  48. Resident work hour limits and patient safety. Poulose BK, Ray WA, Arbogast PG, Needleman J, Buerhaus PI, Griffin MR, Abumrad NN, Beauchamp RD, Holzman MD (2005) Ann Surg 241(6): 847-56; discussion 856-60
    › Primary publication · 15912034 (PubMed) · PMC1357165 (PubMed Central)
  49. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, Shyr Y, Caillouette C, Chakravarthy B (2005) Int J Radiat Oncol Biol Phys 61(5): 1364-70
    › Primary publication · 15817338 (PubMed)
  50. The changing roles of a surgical department chair: adapting to a changing environment. Beauchamp RD (2005) Arch Surg 140(3): 258-63
    › Primary publication · 15781789 (PubMed)
  51. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer. Lawson LL, Sandler M, Martin W, Beauchamp RD, Kelley MC (2004) Am Surg 70(12): 1050-5; discussion 1055-6
    › Primary publication · 15663043 (PubMed)
  52. Department of Surgery, Vanderbilt University Medical Center, Nashville, Tenn. Beauchamp RD (2004) Arch Surg 139(8): 814-5
    › Primary publication · 15302687 (PubMed)
  53. Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Schmidt CR, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS (2004) Surgery 136(2): 303-9
    › Primary publication · 15300195 (PubMed)
  54. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Li JQ, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T, Kuriyama S, Imaida K (2004) Int J Oncol 25(1): 87-95
    › Primary publication · 15201993 (PubMed)
  55. Smad3 has a critical role in TGF-beta-mediated growth inhibition and apoptosis in colonic epithelial cells. Mithani SK, Balch GC, Shiou SR, Whitehead RH, Datta PK, Beauchamp RD (2004) J Surg Res 117(2): 296-305
    › Primary publication · 15047135 (PubMed)
  56. Enhanced tumor formation in cyclin D1 x transforming growth factor beta1 double transgenic mice with characterization by magnetic resonance imaging. Deane NG, Lee H, Hamaamen J, Ruley A, Washington MK, LaFleur B, Thorgeirsson SS, Price R, Beauchamp RD (2004) Cancer Res 64(4): 1315-22
    › Primary publication · 14973059 (PubMed)
  57. Over-expression of cyclin D1 regulates Cdk4 protein synthesis. Parker MA, Deane NG, Thompson EA, Whitehead RH, Mithani SK, Washington MK, Datta PK, Dixon DA, Beauchamp RD (2003) Cell Prolif 36(6): 347-60
    › Primary publication · 14710852 (PubMed)
  58. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Schmidt CR, Washington MK, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS (2003) Am J Surg 186(5): 426-30
    › Primary publication · 14599601 (PubMed)
  59. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA, Beauchamp RD, Prescott SM (2003) J Exp Med 198(3): 475-81
    › Primary publication · 12885872 (PubMed) · PMC2194089 (PubMed Central)
  60. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC (2003) Ann Surg Oncol 10(6): 616-21
    › Primary publication · 12839845 (PubMed)
  61. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp RD, Suzuki K, Alemany R, Harrington K, Vile RG (2003) Nat Biotechnol 21(7): 771-7
    › Primary publication · 12794639 (PubMed)
  62. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Berger DH, O'Mahony CA, Sheng H, Shao J, Albo D, DuBois RN, Beauchamp RD (2003) Surgery 133(5): 568-79
    › Primary publication · 12773985 (PubMed)
  63. Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression. Fujimoto K, Beauchamp RD, Whitehead RH (2002) Gastroenterology 123(6): 1941-8
    › Primary publication · 12454851 (PubMed)
  64. Resistance to transforming growth factor-beta occurs in the presence of normal Smad activation. Berger DH, Feng XH, Yao J, Saha D, Beauchamp RD, Lin X (2002) Surgery 132(2): 310-6
    › Primary publication · 12219028 (PubMed)
  65. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD (2002) J Surg Res 105(1): 43-7
    › Primary publication · 12069500 (PubMed)
  66. Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta(1) in immortalized mouse colonocytes expressing oncogenic Ras. Roman CD, Morrow J, Whitehead R, Beauchamp RD (2002) J Gastrointest Surg 6(3): 304-9
    › Primary publication · 12022979 (PubMed)
  67. Operative technique for safe pulmonary lobectomy in Sprague-Dawley rats. Roman CD, Hanley GA, Beauchamp RD (2002) Contemp Top Lab Anim Sci 41(2): 28-30
    › Primary publication · 11958600 (PubMed)
  68. New strategies for colorectal cancer prevention and treatment. Saha D, Roman C, Beauchamp RD (2002) World J Surg 26(7): 762-6
    › Primary publication · 11948369 (PubMed)
  69. Cyclin D3 is essential for intestinal epithelial cell proliferation. Ko TC, Pan F, Sheng H, Brown DB, Thompson EA, Beauchamp RD (2002) World J Surg 26(7): 812-8
    › Primary publication · 11948368 (PubMed)
  70. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD (2001) Cancer Res 61(14): 5389-95
    › Primary publication · 11454681 (PubMed)
  71. Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Fujimoto K, Sheng H, Shao J, Beauchamp RD (2001) Exp Cell Res 266(2): 239-49
    › Primary publication · 11399052 (PubMed)
  72. Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. Saha D, Datta PK, Beauchamp RD (2001) J Biol Chem 276(31): 29531-7
    › Primary publication · 11371552 (PubMed)
  73. A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Blanke CD, Stipanov M, Morrow J, Rothenberg M, Chinery R, Shyr Y, Coffey R, Johnson DH, Leach SD, Beauchamp RD (2001) Invest New Drugs 19(1): 21-7
    › Primary publication · 11291830 (PubMed)
  74. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN (2000) Neoplasia 2(6): 523-30
    › Primary publication · 11228545 (PubMed) · PMC1508084 (PubMed Central)
  75. TGF-beta and colorectal carcinogenesis. Roman C, Saha D, Beauchamp R (2001) Microsc Res Tech 52(4): 450-7
    › Primary publication · 11170304 (PubMed)
  76. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18(19): 3384-9
    › Primary publication · 11013279 (PubMed)
  77. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Fujimoto K, Hosotani R, Miyamoto Y, Doi R, Koshiba T, Otaka A, Fujii N, Beauchamp RD, Imamura M (2000) Cancer Lett 159(2): 151-8
    › Primary publication · 10996726 (PubMed)
  78. Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL, Beauchamp RD (1999) Neoplasia 1(6): 508-17
    › Primary publication · 10935498 (PubMed) · PMC1508120 (PubMed Central)
  79. Presidential address: evolution. Beauchamp RD (2000) Surgery 128(2): 123-32
    › Primary publication · 10922981 (PubMed)
  80. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. Shao J, Sheng H, DuBois RN, Beauchamp RD (2000) J Biol Chem 275(30): 22916-24
    › Primary publication · 10781597 (PubMed)
  81. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P (2000) Oncogene 19(7): 841-9
    › Primary publication · 10702792 (PubMed)
  82. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD (2000) J Biol Chem 275(9): 6628-35
    › Primary publication · 10692471 (PubMed)
  83. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD (1999) J Nucl Med 40(11): 1784-91
    › Primary publication · 10565771 (PubMed)
  84. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD (1999) Ann Surg Oncol 6(7): 651-7
    › Primary publication · 10560850 (PubMed)
  85. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. O'Mahony CA, Beauchamp RD, Albo D, Tsujii M, Sheng HM, Shao J, Dubois RN, Berger DH (1999) Surgery 126(2): 364-70
    › Primary publication · 10455907 (PubMed)
  86. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD (1999) Ann Surg 229(5): 729-37; discussion 737-8
    › Primary publication · 10235532 (PubMed) · PMC1420818 (PubMed Central)
  87. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Blanke CD, Choy H, Teng M, Beauchamp RD, Leach S, Roberts J, Washington K, Johnson DH (1999) Semin Radiat Oncol 9(2 Suppl 1): 43-52
    › Primary publication · 10210539 (PubMed)
  88. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN (1999) Carcinogenesis 20(2): 185-91
    › Primary publication · 10069452 (PubMed)
  89. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC, Berger DH, DuBois RN, Beauchamp RD (1999) Oncogene 18(4): 855-67
    › Primary publication · 10023661 (PubMed)
  90. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD (1998) J Biol Chem 273(34): 22120-7
    › Primary publication · 9705357 (PubMed)
  91. TGF-beta1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Ko TC, Yu W, Sakai T, Sheng H, Shao J, Beauchamp RD, Thompson EA (1998) Oncogene 16(26): 3445-54
    › Primary publication · 9692552 (PubMed)
  92. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD (1998) Cancer Res 58(11): 2323-7
    › Primary publication · 9622066 (PubMed)
  93. Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK, DuBois RN, Beauchamp RD (1998) Carcinogenesis 19(4): 543-9
    › Primary publication · 9600336 (PubMed)
  94. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Cancer Res 58(2): 362-6
    › Primary publication · 9443418 (PubMed)
  95. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, DuBois RN, Beauchamp RD (1997) Gastroenterology 113(6): 1883-91
    › Primary publication · 9394727 (PubMed)
  96. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ (1997) Nat Med 3(11): 1233-41
    › Primary publication · 9359698 (PubMed)
  97. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN (1997) J Clin Invest 99(9): 2254-9
    › Primary publication · 9151799 (PubMed) · PMC508057 (PubMed Central)
  98. Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Zhang T, Nanney LB, Peeler MO, Williams CS, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD (1997) Cancer Res 57(9): 1638-43
    › Primary publication · 9134999 (PubMed)
  99. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD (1997) Cell Growth Differ 8(4): 463-70
    › Primary publication · 9101092 (PubMed)
  100. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD (1997) Cancer Res 57(1): 169-75
    › Primary publication · 8988060 (PubMed)
  101. Mechanisms of bombesin on growth of gastrinoma (PT) in vivo. Chu KU, Ishizuka J, Battey JF, Uchida T, Beauchamp RD, Townsend CM, Thompson JC (1996) Dig Dis Sci 41(11): 2180-6
    › Primary publication · 8943970 (PubMed)
  102. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN (1996) Gastroenterology 111(4): 1134-40
    › Primary publication · 8831610 (PubMed)
  103. Short-term caloric restriction augments age-related decreases in gastrin content and release. Chu KU, Evers BM, Ishizuka J, Beauchamp RD, Greeley GH, Townsend CM, Thompson JC (1996) Mech Ageing Dev 87(1): 25-33
    › Primary publication · 8735904 (PubMed)
  104. Intestinal cell cycle regulations. Interactions of cyclin D1, Cdk4, and p21Cip1. Beauchamp RD, Sheng HM, Shao JY, Thompson EA, Ko TC (1996) Ann Surg 223(5): 620-7; discussion 627-8
    › Primary publication · 8651753 (PubMed) · PMC1235195 (PubMed Central)
  105. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996) Cancer Res 56(4): 733-7
    › Primary publication · 8631005 (PubMed)
  106. Novel action of transforming growth factor beta 1 in functioning human pancreatic carcinoid cells. Ishizuka J, Beauchamp RD, Sato K, Townsend CM, Thompson JC (1993) J Cell Physiol 156(1): 112-8
    › Primary publication · 8391003 (PubMed)
  107. Transforming growth factor-beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. Ko TC, Beauchamp RD, Townsend CM, Thompson EA, Thompson JC (1994) Am J Surg 167(1): 14-9; discussion 19-20
    › Primary publication · 8311125 (PubMed)
  108. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Parekh D, Ishizuka J, Townsend CM, Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley G, Thompson JC (1994) Pancreas 9(1): 83-90
    › Primary publication · 8108375 (PubMed)
  109. Activation of hepatic proliferation-associated transcription factors by lipopolysaccharide. Beauchamp RD, Papaconstantinou J, Henderson AM, Sheng HM, Townsend CM, Thompson JC (1994) Surgery 116(2): 367-76; discussion 376-7
    › Primary publication · 8048002 (PubMed)
  110. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ (1995) Gastroenterology 108(2): 564-80
    › Primary publication · 7835600 (PubMed)
  111. Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD (1995) Oncogene 10(1): 177-84
    › Primary publication · 7824270 (PubMed)
  112. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Sumi S, Beauchamp RD, Townsend CM, Pour PM, Ishizuka J, Thompson JC (1994) Pancreas 9(5): 657-61
    › Primary publication · 7809022 (PubMed)
  113. Phorbol ester-induced alteration in the pattern of secretion and storage of chromogranin A and neurotensin in a human pancreatic carcinoid cell line. Zhang T, Townsend CM, Udupi V, Yanaihara N, Rajaraman S, Beauchamp RD, Ishizuka J, Evers BM, Gomez G, Thompson JC (1995) Endocrinology 136(5): 2252-61
    › Primary publication · 7720675 (PubMed)
  114. Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Ko TC, Beauchamp RD, Townsend CM, Thompson JC (1993) Surgery 114(2): 147-53; discussion 153-4
    › Primary publication · 7688149 (PubMed)
  115. Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells. Guo YS, Beauchamp RD, Jin GF, Townsend CM, Thompson JC (1993) Gastroenterology 104(6): 1595-604
    › Primary publication · 7684715 (PubMed)
  116. Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. Guo YS, Jin GF, Townsend CM, Zhang T, Sheng HM, Beauchamp RD, Thompson JC (1995) J Am Coll Surg 181(2): 145-54
    › Primary publication · 7627387 (PubMed)
  117. Differential regulation by TGF-beta 1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells. Guo YS, Townsend CM, Jin GF, Beauchamp RD, Thompson JC (1995) Am J Physiol 268(6 Pt 1): E1199-204
    › Primary publication · 7541944 (PubMed)
  118. Potentiation of apomorphine and D-amphetamine effects by naloxone. Adams PM, Beauchamp R, Alston C (1981) Life Sci 28(6): 629-34
    › Primary publication · 7193793 (PubMed)
  119. Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation. Nealon WH, Beauchamp RD, Townsend CM, Thompson JC (1987) Am J Surg 153(1): 96-101
    › Primary publication · 3799899 (PubMed)
  120. Diagnostic role of gastrointestinal hormones in patients with chronic pancreatitis. Nealon WH, Beauchamp RD, Townsend CM, Boyd G, Shabot M, Thompson JC (1986) Ann Surg 204(4): 430-7
    › Primary publication · 3767478 (PubMed) · PMC1251314 (PubMed Central)
  121. Inhibition of pentagastrin-stimulated up-regulation of gastrin receptors and growth of mouse colon tumor in vivo by proglumide, a gastrin receptor antagonist. Singh P, Le S, Beauchamp RD, Townsend CM, Thompson JC (1987) Cancer Res 47(19): 5000-4
    › Primary publication · 3621187 (PubMed)
  122. Growth factors and intestinal neoplasms. Townsend CM, Beauchamp RD, Singh P, Thompson JC (1988) Am J Surg 155(3): 526-36
    › Primary publication · 3278641 (PubMed)
  123. Inhibition of human gastric adenocarcinoma xenograft growth in nude mice by alpha-difluoromethylornithine. Upp JR, Beauchamp RD, Townsend CM, Barranco SC, Singh P, Rajaraman S, James E, Thompson JC (1988) Cancer Res 48(11): 3265-9
    › Primary publication · 3130188 (PubMed)
  124. Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice. Beauchamp RD, Townsend CM, Singh P, Glass EJ, Thompson JC (1985) Ann Surg 202(3): 303-9
    › Primary publication · 2994583 (PubMed) · PMC1250901 (PubMed Central)
  125. Combined endoscopic and fluoroscopic balloon dilatation of a complex proximal jejunal stricture. Nealon WH, Beauchamp RD, Halpert R, Thompson JC (1989) Surgery 105(1): 113-6
    › Primary publication · 2911798 (PubMed)
  126. Operative strategies in the management of mediastinal pancreatic pseudocyst. Beauchamp RD, Winsett M, Nealon WH (1989) Surgery 106(3): 567-70
    › Primary publication · 2772831 (PubMed)
  127. Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. Beauchamp RD, Barnard JA, McCutchen CM, Cherner JA, Coffey RJ (1989) J Clin Invest 84(3): 1017-23
    › Primary publication · 2760208 (PubMed) · PMC329750 (PubMed Central)
  128. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL (1989) Proc Natl Acad Sci U S A 86(5): 1578-82
    › Primary publication · 2466294 (PubMed) · PMC286741 (PubMed Central)
  129. Proglumide inhibits cholecystokinin and meal-stimulated pancreatic secretion and release of pancreatic polypeptide. Beauchamp RD, Gomez G, Nealon WH, Townsend CM, Greeley GH, Thompson JC (1990) Surgery 108(3): 553-8
    › Primary publication · 2396199 (PubMed)
  130. Additive interactions of calcitonin gene-related peptide and calcitonin on pancreatic exocrine function in conscious dogs. Nealon WH, Beauchamp RD, Townsend CM, Thompson JC (1990) Surgery 107(4): 434-41
    › Primary publication · 2321138 (PubMed)
  131. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ, Moses HL (1990) Pancreas 5(4): 369-80
    › Primary publication · 2199964 (PubMed)
  132. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) Proc Natl Acad Sci U S A 87(4): 1486-90
    › Primary publication · 2137615 (PubMed) · PMC53500 (PubMed Central)
  133. Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice. Saydjari R, Beauchamp RD, Townsend CM, Thompson JC (1991) Cancer Lett 58(1-2): 155-8
    › Primary publication · 2049780 (PubMed)
  134. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Beauchamp RD, Coffey RJ, Lyons RM, Perkett EA, Townsend CM, Moses HL (1991) Cancer Res 51(19): 5253-60
    › Primary publication · 1913648 (PubMed)
  135. Posttranscriptional regulation of neurotensin in the gut. Evers BM, Beauchamp RD, Ishizuka J, Townsend CM, Alam T, Papaconstantinou J, Thompson JC (1991) Surgery 110(2): 247-52
    › Primary publication · 1858034 (PubMed)
  136. The role of endogenous prostaglandins in hormone-stimulated pancreatic exocrine secretion. Beauchamp RD, MacLellan DG, Upp JR, Nealon WH, Townsend CM, Thompson JC (1992) Gastroenterology 102(1): 272-9
    › Primary publication · 1727759 (PubMed)
  137. Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. Kim SW, Beauchamp RD, Townsend CM, Thompson JC (1991) Surgery 110(2): 270-5; discussion 276
    › Primary publication · 1713357 (PubMed)
  138. Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells. Parekh D, Ishizuka J, Townsend CM, Haber BE, Beauchamp RD, Rajaraman S, Karp G, Hsieh J, Thompson JC (1991) Arch Surg 126(4): 467-72
    › Primary publication · 1706915 (PubMed)
  139. Increased production of transforming growth factor alpha following acute gastric injury. Polk WH, Dempsey PJ, Russell WE, Brown PI, Beauchamp RD, Barnard JA, Coffey RJ (1992) Gastroenterology 102(5): 1467-74
    › Primary publication · 1568557 (PubMed)
  140. Transforming growth factor-beta (TGF-beta 1) inhibits pancreatic acinar cell growth. Logsdon CD, Keyes L, Beauchamp RD (1992) Am J Physiol 262(2 Pt 1): G364-8
    › Primary publication · 1539670 (PubMed)
  141. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC (1992) Gastroenterology 103(3): 982-9
    › Primary publication · 1499946 (PubMed)
  142. Bombesin stimulates growth of human gastrinoma. Chung DH, Evers BM, Beauchamp RD, Upp JR, Rajaraman S, Townsend CM, Thompson JC (1992) Surgery 112(6): 1059-65
    › Primary publication · 1455308 (PubMed)
  143. Transforming growth factor (TGF)-beta stimulates hepatic jun-B and fos-B proto-oncogenes and decreases albumin mRNA. Beauchamp RD, Sheng HM, Ishizuka J, Townsend CM, Thompson JC (1992) Ann Surg 216(3): 300-7; discussion 307-8
    › Primary publication · 1417179 (PubMed) · PMC1242612 (PubMed Central)
  144. Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1. Beauchamp RD, Sheng HM, Bascom CC, Miller DA, Lyons RM, Torre-Amione G, Moses HL (1992) Endocrinology 130(5): 2476-86
    › Primary publication · 1374006 (PubMed)
  145. Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Ishizuka J, Beauchamp RD, Evers BM, Townsend CM, Thompson JC (1992) Biochem Biophys Res Commun 185(2): 577-81
    › Primary publication · 1351720 (PubMed)
  146. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. Ishizuka J, Beauchamp RD, Townsend CM, Greeley GH, Thompson JC (1992) J Cell Physiol 150(1): 1-7
    › Primary publication · 1309821 (PubMed)
  147. Effect of a cholecystokinin antagonist, proglumide, on cholecystokinin-8-induced gallbladder contraction in conscious dogs. Fujimura M, Sakamoto T, Lluis F, Beauchamp RD, Townsend CM, Greeley GH, Thompson JC (1992) Biol Signals 1(2): 94-100
    › Primary publication · 1307918 (PubMed)
  148. Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Beauchamp RD, Sheng HM, Alam T, Townsend CM, Papaconstantinou J (1992) Mol Endocrinol 6(11): 1789-96
    › Primary publication · 1282669 (PubMed)